Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for MCUJF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: MCUJF is a Sell candidate.
MCUJF stock price ended at $0.94 on 星期四, after rising 5.62%
On the latest trading day Jan 22, 2026, the stock price of MCUJF rose by 5.62%, climbing from $0.94 to $0.94. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.94 and a high of $0.94. Alongside this price increase, trading volume also rose by 3.1K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 105 shares were traded, amounting to a market value of approximately $9.8M.